You are using an outdated browser. Please upgrade your browser to improve your experience.
AFib CDA

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians

AFib CDA

by Clinical Support Systems
AFib CDA
AFib CDA
AFib CDA

What is it about?

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid that assists clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation.

AFib CDA

App Details

Version
1.5.1
Rating
NA
Size
7Mb
Genre
Medical Health & Fitness
Last updated
December 19, 2012
Release date
August 29, 2011
More info

App Screenshots

AFib CDA screenshot-0
AFib CDA screenshot-1
AFib CDA screenshot-2
AFib CDA screenshot-3

App Store Description

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid that assists clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation.

This iPad Application allows physicians to accurately and efficiently estimate an individual patient’s baseline annual absolute risk of stroke and bleeding using the CHA2DS2-VASc and HAS-BLED scoring systems.

The Clinical Decision Aid then identifies the antithrombotic agent that is associated with the lowest Net Risk to the patient, and recommends an optimal antithrombotic regime for the prevention of stroke based upon the patient’s particular CHA2DS2VASc and HAS-BLED Scores.